If you or someone you know has been impacted by pancreatic cancer, you understand the devastating prognosis often associated with this disease. A new drug, Darovasertib, is showing remarkable promise by tackling a previously 'undruggable' target, offering a glimmer of hope where little existed before.
Darovasertib is trending because it's showing unprecedented results in treating metastatic uveal melanoma and now, pancreatic cancer, a disease notorious for its poor survival rates.
Pancreatic cancer has a 5-year survival rate of only about 12%, making any significant breakthrough highly impactful.